Cargando…
Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stab...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237144/ https://www.ncbi.nlm.nih.gov/pubmed/32440564 http://dx.doi.org/10.1002/btm2.10159 |
_version_ | 1783536269051035648 |
---|---|
author | Chang, Rachel Yoon Kyung Kwok, Philip Chi Lip Khanal, Dipesh Morales, Sandra Kutter, Elizabeth Li, Jian Chan, Hak‐Kim |
author_facet | Chang, Rachel Yoon Kyung Kwok, Philip Chi Lip Khanal, Dipesh Morales, Sandra Kutter, Elizabeth Li, Jian Chan, Hak‐Kim |
author_sort | Chang, Rachel Yoon Kyung |
collection | PubMed |
description | Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stabilization mechanism is yet unknown. This paper reports the first study investigating the stabilization mechanism for phages in these powders. Proteins and other biologics are known to be preserved in dry state within a glassy sugar matrix at storage temperatures (T (s)) at least ~50°C below the glass transition temperature (T (g)). This is because at (T (g) − T (s)) >50°C, molecules are sufficiently immobilized with reduced reactivity. We hypothesized that this glass stabilization mechanism may also be applicable to phages comprising mostly of proteins. In this study, spray dried powders of Pseudomonas phage PEV20 containing lactose and leucine as excipients were stored at 5, 25 or 50°C and 15 or 33% relative humidity (RH), followed by assessment of bioactivity (PEV20 stability) and physical properties. PEV20 was stable with negligible titer loss after storage at 5°C/15% RH for 250 days, while storage at 33% RH caused increased titer losses of 1 log(10) and 3 log(10) at 5 and 25°C, respectively. The plasticizing effect of water at 33% RH lowered the T (g) by 30°C, thus narrowing the gap between T (s) and T (g) to 19–28°C, which was insufficient for glass stabilization. In contrast, the (T (g) − T (s)) values were higher (range, 46–65°C) under the drier condition of 15% RH, resulting in the improved stability which corroborated with the vitrification hypothesis. Furthermore, phage remained stable (≤1 log(10)) when the (T (g) − T (s)) value lay between 26–48°C, but became inactivated as the value fell below 20°C. In conclusion, this study demonstrated that phage can be sufficiently stabilized in spray dried powders by keeping the (T (g) − T (s)) value above 46°C, thus supporting the vitrification hypothesis that phages are stabilized by immobilization inside a rigid glassy sugar matrix. These findings provide a guide to better manufacture and storage practices of inhaled phage powder products using for translational medicines. |
format | Online Article Text |
id | pubmed-7237144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72371442020-05-21 Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization Chang, Rachel Yoon Kyung Kwok, Philip Chi Lip Khanal, Dipesh Morales, Sandra Kutter, Elizabeth Li, Jian Chan, Hak‐Kim Bioeng Transl Med Research Reports Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stabilization mechanism is yet unknown. This paper reports the first study investigating the stabilization mechanism for phages in these powders. Proteins and other biologics are known to be preserved in dry state within a glassy sugar matrix at storage temperatures (T (s)) at least ~50°C below the glass transition temperature (T (g)). This is because at (T (g) − T (s)) >50°C, molecules are sufficiently immobilized with reduced reactivity. We hypothesized that this glass stabilization mechanism may also be applicable to phages comprising mostly of proteins. In this study, spray dried powders of Pseudomonas phage PEV20 containing lactose and leucine as excipients were stored at 5, 25 or 50°C and 15 or 33% relative humidity (RH), followed by assessment of bioactivity (PEV20 stability) and physical properties. PEV20 was stable with negligible titer loss after storage at 5°C/15% RH for 250 days, while storage at 33% RH caused increased titer losses of 1 log(10) and 3 log(10) at 5 and 25°C, respectively. The plasticizing effect of water at 33% RH lowered the T (g) by 30°C, thus narrowing the gap between T (s) and T (g) to 19–28°C, which was insufficient for glass stabilization. In contrast, the (T (g) − T (s)) values were higher (range, 46–65°C) under the drier condition of 15% RH, resulting in the improved stability which corroborated with the vitrification hypothesis. Furthermore, phage remained stable (≤1 log(10)) when the (T (g) − T (s)) value lay between 26–48°C, but became inactivated as the value fell below 20°C. In conclusion, this study demonstrated that phage can be sufficiently stabilized in spray dried powders by keeping the (T (g) − T (s)) value above 46°C, thus supporting the vitrification hypothesis that phages are stabilized by immobilization inside a rigid glassy sugar matrix. These findings provide a guide to better manufacture and storage practices of inhaled phage powder products using for translational medicines. John Wiley & Sons, Inc. 2020-04-14 /pmc/articles/PMC7237144/ /pubmed/32440564 http://dx.doi.org/10.1002/btm2.10159 Text en © 2020 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Reports Chang, Rachel Yoon Kyung Kwok, Philip Chi Lip Khanal, Dipesh Morales, Sandra Kutter, Elizabeth Li, Jian Chan, Hak‐Kim Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization |
title | Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization |
title_full | Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization |
title_fullStr | Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization |
title_full_unstemmed | Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization |
title_short | Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization |
title_sort | inhalable bacteriophage powders: glass transition temperature and bioactivity stabilization |
topic | Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237144/ https://www.ncbi.nlm.nih.gov/pubmed/32440564 http://dx.doi.org/10.1002/btm2.10159 |
work_keys_str_mv | AT changrachelyoonkyung inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization AT kwokphilipchilip inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization AT khanaldipesh inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization AT moralessandra inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization AT kutterelizabeth inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization AT lijian inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization AT chanhakkim inhalablebacteriophagepowdersglasstransitiontemperatureandbioactivitystabilization |